| Literature DB >> 30181422 |
Jerald P Radich, Michael Deininger, Camille N Abboud, Jessica K Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M Kantarjian, Lori Maness, Leland Metheny, Joseph O Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G Rose, Neil P Shah, B Douglas Smith, David S Snyder, Kendra L Sweet, Moshe Talpaz, James Thompson, David T Yang, Kristina M Gregory, Hema Sundar.
Abstract
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30181422 DOI： 10.6004/jnccn.2018.0071
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908